NLRC5 Antibody - #DF13672

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(3)   (5)  
产品: NLRC5 抗体
货号: DF13672
描述: Rabbit polyclonal antibody to NLRC5
应用: WB IHC
文献验证: WB, IHC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
蛋白号: Q86WI3
RRID: AB_2846691

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1500 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
NLRC5 Antibody detects endogenous levels of total NLRC5.
RRID:
AB_2846691
引用格式: Affinity Biosciences Cat# DF13672, RRID:AB_2846691.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Caterpiller protein 16.1; CLR16.1; FLJ21709; FLJ39711; NLR family, CARD domain containing 5; NLR family, CARD-containing 5; NLR family, caspase recruitment domain-containing 5; NLRC5; NLRC5_HUMAN; NOD-like receptor C5; NOD27; NOD4; Nucleotide-binding oligomerization domain protein 27; Nucleotide-binding oligomerization domain protein 4; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain containing 5; nucleotide-binding oligomerization domains 27; OTTHUMP00000164675; Protein Caterpiller 16.1; Protein NLRC5;

抗原和靶标

免疫原:

A synthesized peptide derived from human NLRC5, corresponding to a region within the internal amino acids.

基因/基因ID:
NLRC5(84166)

文献引用

1). LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. CANCER LETTERS, 2022 (PubMed: 34974132) [IF=9.1]

Application: WB    Species: Mouse    Sample: EC cells

Fig. 5. Overexpression of LC3 inhibits the expressions of NLRC5 and MHC-I genes in EC cells. A Representative western blotting and qRT-PCR results showing successful constructions of LC3 plasmid. B-D Representative western blotting and qRT-PCR results showing that the overexpression of LC3 downregulates the levels of NLRC5 and the MHC-I genes, HLA-A, LMP2, TAP1, and β2-M, in HEC-1A, AN3CA, and Ishikawa cells (**P < 0.01 vs. vector group). The expression levels of mRNA were normalized using β-actin mRNA levels and calculated using the 2− ΔΔCt method. Protein expression levels were quantified using the Image J software and normalized using β-actin protein levels. The results are represented as the mean ± SEM from at least three independent experiments.
2). NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer. Translational oncology, 2023 (PubMed: 37531863) [IF=4.5]

Application: WB    Species: human    Sample: HEC-1A and HEC-1B cells

Fig. 1. NLRC5 inhibits EC cell growth by activating CD8+ T cells in vitro. (a) NLRC5 protein and mRNA expression in HEC-1A and HEC-1B cells with or without NLRC5 overexpression (**P < 0.01 vs. Vector group). (b) The purity of CD8+ T cells in peripheral blood mononuclear cells (PBMCs) isolated from lymphocyte separation medium (left) and after magnetic bead sorting (right). (c) The proliferation of CD8+ T cells in the coculture system (**P < 0.01 vs. Vector group). (d) The proliferation of HEC-1A and HEC-1B cells in the coculture system (**P < 0.01 vs. Vector group). (e) The migration of HEC-1A and HEC-1B cells in the coculture system (Scale bar: 100 μm, **P < 0.01 vs. Vector group). (f) The apoptosis of HEC-1A and HEC-1B cells in the coculture system (**P < 0.01 vs. Vector group).

Application: IHC    Species: human    Sample: HEC-1A and HEC-1B cells

Fig. 1. NLRC5 inhibits EC cell growth by activating CD8+ T cells in vitro. (a) NLRC5 protein and mRNA expression in HEC-1A and HEC-1B cells with or without NLRC5 overexpression (**P < 0.01 vs. Vector group). (b) The purity of CD8+ T cells in peripheral blood mononuclear cells (PBMCs) isolated from lymphocyte separation medium (left) and after magnetic bead sorting (right). (c) The proliferation of CD8+ T cells in the coculture system (**P < 0.01 vs. Vector group). (d) The proliferation of HEC-1A and HEC-1B cells in the coculture system (**P < 0.01 vs. Vector group). (e) The migration of HEC-1A and HEC-1B cells in the coculture system (Scale bar: 100 μm, **P < 0.01 vs. Vector group). (f) The apoptosis of HEC-1A and HEC-1B cells in the coculture system (**P < 0.01 vs. Vector group).
3). NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency. Scientific reports, 2024 (PubMed: 38822039) [IF=3.8]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.